Avalyn Pharma (AVLN) vs Bicara Therapeutics (BCAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.13 billion vs $1.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | BCAX |
|---|---|---|
| Share price | $25.53 | $16.42 |
| Market cap | $1.13B | $1.09B |
| 1-day change | +0.39% | -0.85% |
| YTD return | — | -2.44% |
| 1-year return | — | -9.63% |
| EPS (TTM) | $-2.49 | $-3.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $30.99 |
| 52-week low | $24.15 | $13.70 |
| Distance from 52-week high | -36.45% | -47.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +142.07% | +116.20% |
| Average volume | 235.31K | 605.61K |
| Shares outstanding | 44.33M | 66.17M |
| Employees | 55 | 103 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Healthcare · Biotechnology · 55 employees
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Healthcare · Biotechnology · 103 employees
AVLN vs BCAX FAQ
Which is bigger, Avalyn Pharma or Bicara Therapeutics?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.13B compared with $1.09B for Bicara Therapeutics (BCAX).
Are Avalyn Pharma and Bicara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.